Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028899 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00028899 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 47 participants.
The verdict
NCT00028899, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with combination chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining gemtuzumab ozogamicin with combination chemotherapy in treating children who have relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Interventions
- DRUG cytarabine
- DRUG gemtuzumab ozogamicin
- DRUG asparaginase
- DRUG mitoxantrone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2002-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028899
The ClinicalTrials.gov registry entry for NCT00028899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cytarabine is the first listed.
NCT00028899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028899 about?
NCT00028899 is a clinical study titled "Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes". RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Com...
What is the current status of trial NCT00028899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2002-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00028899?
The interventions under investigation include: cytarabine (DRUG), gemtuzumab ozogamicin (DRUG), asparaginase (DRUG), mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00028899?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.